Rationale for combination therapy of chronic myelogenous leukaemia with imatinib and irradiation or alkylating agents: implications for pretransplant conditioning

The tyrosine kinase activity of the BCR–ABL oncoprotein results in reduced apoptosis and thus prolongs survival of chronic myelogenous leukaemia cells. The tyrosine kinase inhibitor imatinib (formerly STI571) was reported to selectively suppress the proliferation of BCR–ABL-positive cells. Assuming...

Descripción completa

Detalles Bibliográficos
Autores principales: Topaly, J, Fruehauf, S, Ho, A D, Zeller, W J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2002
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375375/
https://www.ncbi.nlm.nih.gov/pubmed/11986785
http://dx.doi.org/10.1038/sj.bjc.6600242

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375375/
https://www.ncbi.nlm.nih.gov/pubmed/11986785
http://dx.doi.org/10.1038/sj.bjc.6600242

Ejemplares similares